pitrakinra trade name aerovant human recombinant protein wildtype human antagonist studied phase iib clinical trial treatment asthma two point mutations pitrakinra position mutated arginine aspartic acid position mutated tyrosine aspartic acid confer ability block signaling preventing assembly receptor alpha either upregulation cytokines including thought critical allergic inflammation associated atopic diseases asthma eczema targets pitrakinra action inflammatory cells dendritic cells cells b cells structural cells smooth muscle endothelium epithelium express drug applied subcutaneous injection inhalation latter formulation proved asthma results dysregulated hyperresponsive immune response airways immune cells allergic asthmatics respond aggressively foreign allergens release two key mediators initiate cycle inflammation lung pitrakinra antagonist receptor alpha chain protein also part thereby blocks inflammatory effects interrupting lymphocyte immune pitrakinra protects allergic cynomolgus monkeys allergeninduced airways hyperresponsiveness lung eosinophilia prophylactic therapeutic model settings subcutaneous injection pitrakinra human patients severe atopic eczema weeks decreases eczema clinical score circulating ige concentrations normalized tcell subsets decreases forced expiratory volume allergen challenge weeks inhalation pitrakinra supports hypothesis dual inhibition affect course late asthmatic response experimental allergen challenge reduced frequency spontaneous asthma attacks requiring rescue medication use suggests use pitrakinra improves control asthma addition improvements late asthmatic response measurement fractional expiratory nitric oxide feno indicates resting inflammatory status lungs significantly attenuated inhalation pitrakinra weeks result supports observations proinflammatory mediators induce nitric oxide synthase inos epithelial cells basal feno could dependent upregulation inos whereas increase feno allergen challenge could involve additional pathways epithelial cells perhaps macrophages affected inhibition pitrakinra may downregulate baseline inflammation asthmatic lung interfering lung natural defenses contact large amounts foreign pitrakinra associated adverse effect whether administered subcutaneous injection inhalation participants atopic asthma atopic eczema common adverse event subcutaneous administration injection siterelated discomfort common event injectable drugs however events neither associated development antibodies discernible pattern ie common end weeks exposure also fewer spontaneous asthma attacks respiratoryrelated adverse events require rescue medication participants received pitrakinra subcutaneously placebo httpsenwikipediaorgwikipitrakinra